Skip to main content

About your Search

20130124
20130201
STATION
CNBC 2
LANGUAGE
Search Results 0 to 1 of about 2
CNBC
Jan 31, 2013 3:00pm EST
industrials 13,875. >> up next, we'll talk with aetna chairman and ceo mark bertolini. the stock down slightly after the report on earnings. >> president obama's health care reform, you have of the law has taken effect, union leaders are having buyers remorse. we'll tell you why next. >> and our own jeff cox says he's not a believer in the rally. that's coming up on the "closing bell." stay with us. [ male announcer ] you are a business pro. omnipotent of opportunity. you know how to mix business... with business. and you...rent from national. because only national lets you choose any car in the aisle. and go. you can even take a full-size or above. and still pay the mid-size price. i could get used to this. [ male announcer ] yes, you could business pro. yes, you could. go national. go like a pro. >>> when it really mattered, they supported it. now some unions are turning against president obama's health care reform. eamon javers has the details. >> reporter: hi, scott. some unexpected price hikes could be causing headaches for some unions in terms of the president's new health care law and t
CNBC
Jan 29, 2013 6:00am EST
of money to develop them. but then again, we all have this problem with keeping health care costs down and obama care wants generic competition for biologics. what's the right road to take there? >> you know, joe, we've been in this industry for over 135 years. for us, we've taken a focus and we pursue both small molecule as well as bioological routes to address some of the most oppressing diseases out there. if you take alzheimer's, we have the biologic but we have a base inhibitor in phase two -- >> would you pay a lobbyist, would you get lobbyists for eli lilly to try to make it that you don't have to have generic competition for biologics, is that something eli lilly would do, or do you go along with it? >> well, remember, in the affordable care act we did get an extension in terms of data protection, as we should be, to at least 12 years. we believe that's very important for us to have a reasonable period to generate return on investment that we make in r&d. we still are the industry that invests the most in r&d, research and development, in this country. we from a policy standpoi
Search Results 0 to 1 of about 2